U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

  1. Home
  2. About FDA
  3. FDA Organization
  4. Center for Drug Evaluation and Research (CDER)
  5. CDER Offices and Divisions
  6. Office of Cardiology, Hematology, Endocrinology and Nephrology (OCHEN) - Division of Cardiology and Nephrology (DCN)
  1. CDER Offices and Divisions

Office of Cardiology, Hematology, Endocrinology and Nephrology (OCHEN) - Division of Cardiology and Nephrology (DCN)


The Division of Cardiology and Nephrology (DCN) regulates and reviews Investigational New Drug (IND) applications and marketing applications for drug and biologic products for the treatment of cardiovascular and kidney conditions and diseases, such as: acute coronary syndrome, heart failure, hypertension, peripheral arterial disease, pulmonary hypertension, cardiac arrhythmias, chronic kidney diseases, acute kidney injury, and glomerular diseases. DCN also regulates peritoneal dialysis solutions and replacement solutions for continuous renal replacement therapies, as well as products for the treatment of hyperphosphatemia in patients with chronic kidney disease and hyperkalemia.

Contact Us

Mailing Address:

Food and Drug Administration
Center for Drug Evaluation and Research
Division of Cardiology and Nephrology
10903 New Hampshire Avenue, Silver Spring, MD 20993
Building 22, Suite 4177
Phone: (301) 796-2240
Fax: (301) 796-9838




Back to Top